Vitamin D3 for Life

Live Enlightened

Article

Cellular uptake and intracellular handling of vitamin D metabolites: Study Summary

Previous related pageCellular uptake and intracellular handling of vitamin D metabolites: Full Evidence ReviewNext related pageEnzymatic inactivation pathways of vitamin D metabolites: Full Evidence Review
Study at a glance

How does vitamin D get inside cells?

Cells must take in vitamin D before they can activate or break it down. Most vitamin D compounds in the blood are attached to a carrier called vitamin D-binding protein. Some cells use surface proteins called megalin and cubilin to take in these attached compounds. Cells can also get vitamin D compounds that are not attached to the carrier.

How do the kidneys recover vitamin D?

Kidney cells recover vitamin D attached to its carrier from filtered fluid. This prevents vitamin D from being lost in urine and supplies material for activation. In one experiment, blocking this process reduced uptake to about 8.2% of the untreated comparison. In an animal model lacking megalin, blood 25-hydroxyvitamin D fell by about 80%. These results show the importance of this recovery system under the tested conditions.

Do all tissues take in vitamin D in the same way?

Some breast, muscle and stem-cell experiments also linked uptake through surface proteins to vitamin D processing or cell responses. However, uptake differed between cell types and stages of development. Muscle and fat-cell models did not follow the same pattern. The presence of megalin in the parathyroid glands has not been adequately tested as a vitamin D entry route.

Can a blood test show how much vitamin D reaches cells?

Experiments without the carrier protein show that getting vitamin D compounds that are not attached to it remains important for cells. No single entry route has been proven for every tissue. Studies of kidney disease have produced different findings. They also show changes that may partly make up for reduced uptake. A total blood vitamin D result cannot, by itself, show how much reaches the inside of every cell.

Read the full article below ↓

Vitamin D metabolism inside a cell begins with substrate access. Khan and colleagues review why this step differs across tissues: most circulating 25-hydroxyvitamin D [25(OH)D] is bound to vitamin D-binding protein (DBP), yet cells do not all use the same mechanism to obtain it. Renal proximal tubular cells have a specialised megalin/cubilin endocytic system, while many other tissues remain compatible with greater dependence on free or bioavailable metabolite.

Why renal uptake matters

In the kidney, filtered DBP-bound vitamin D is recovered by megalin-dependent endocytosis rather than being lost in urine. Receptor-associated protein (RAP), an inhibitor of megalin-mediated uptake, reduced renal DBP uptake in a key experiment to about 8.2% of untreated control. Megalin deficiency also caused a roughly 80% fall in plasma 25(OH)D in the classic work reviewed, accompanied by severe skeletal consequences.

This is metabolically important because proximal tubular cells contain CYP27B1. Recovered 25(OH)D can therefore become intracellular substrate for conversion to 1,25-dihydroxyvitamin D [1,25(OH)2D]. Uptake is part of the activation system, not merely a transport detail.

Extrarenal uptake is functional but heterogeneous

Functional receptor-mediated uptake has been demonstrated outside the kidney. Mammary-cell DBP uptake was temperature dependent and RAP sensitive. Differentiated myotubes accumulated labelled 25(OH)D at roughly two: to three-fold higher levels than myoblasts, and RAP reduced myotube uptake by 66% over 16 hours. Human mesenchymal stem-cell work also linked lower megalin activity to reduced local 1,25(OH)2D biosynthesis and weaker precursor-dependent osteoblastogenic responses.

These examples do not establish a universal extrarenal pathway. Adipocyte differentiation showed a different pattern, and parathyroid megalin has calcium-sensing evidence but has not been adequately tested as a vitamin D uptake mechanism.

The essential qualification

DBP-null models show that free-metabolite access remains biologically relevant. The defensible model therefore contains both receptor-mediated uptake and free or bioavailable entry, with their relative importance determined by tissue, receptor expression, differentiation state and disease context.

Kidney disease further illustrates the limits of simple conclusions. Several CKD and diabetic-nephropathy models show lower megalin expression and increased urinary loss of DBP and vitamin D metabolites, but findings are not completely consistent across species and studies. The source supports tissue-specific substrate handling and compensatory responses, not one universal cellular entry mechanism.

This substrate-access step sits upstream of Vitamin D Metabolism at the Cellular Level and helps explain why Vitamin D Intracrine Activity can differ between tissues.

Primary source

Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.

The Full Evidence Review develops the receptor biology, quantitative experiments and disease-model qualifications in full.

Related reading

Original sources

Source

Read the full paper

Khan SS, Petkovich M, Holden RM, Adams MA.

Publication details

Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.

Read more →